Evidence map›Paper›PMID 36012707›Full record

ArticleInternational journal of molecular sciences2022

Serotonin 5-HT

Krzysztof Więckowski, Natalia Szałaj, Beata Gryzło, Tomasz Wichur, Izabella Góral, Emilia Sługocka, Joanna Sniecikowska, Gniewomir Latacz, Agata Siwek, Justyna Godyń and 3 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Krzysztof WięckowskiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.
Natalia SzałajDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.
Beata GryzłoDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.
Tomasz WichurDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.
Izabella GóralDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.ORCID 0000-0002-1233-5663
Emilia SługockaDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.ORCID 0000-0001-5355-577X
Joanna SniecikowskaDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.ORCID 0000-0002-5296-7964
Gniewomir LataczDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.ORCID 0000-0001-9247-2598
Agata SiwekDepartment of Pharmacobiology, Faculty of Pharmacy Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.
Justyna GodyńDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.ORCID 0000-0002-0295-2772
Adam BuckiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.ORCID 0000-0003-0451-9814
Marcin KołaczkowskiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.
Anna WięckowskaDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.ORCID 0000-0003-2549-170X

Funding

National Science Center 2016/23/D/NZ7/01328
6 · The paper itself

Abstract

Neurodegeneration leading to Alzheimer's disease results from a complex interplay of a variety of processes including misfolding and aggregation of amyloid beta and tau proteins, neuroinflammation or oxidative stress. Therefore, to address more than one of these, drug discovery programmes focus on the development of multifunctional ligands, preferably with disease-modifying and symptoms-reducing potential. Following this idea, herein we present the design and synthesis of multifunctional ligands and biological evaluation of their 5-HT

Indexed as

Alzheimer DiseaseCholinesterase InhibitorsAcetylcholinesteraseAmyloid beta-PeptidesAntioxidantsButyrylcholinesteraseChelating AgentsDrug DesignHumansLigandsReceptors, SerotoninSerotoninStructure-Activity RelationshipAcetylcholinesteraseAmyloid beta-PeptidesAntioxidantsButyrylcholinesteraseChelating AgentsCholinesterase InhibitorsLigandsReceptors, SerotoninSerotoninserotonin 6 receptor5-HT6 receptor ligandsAChEAlzheimer’s diseaseantioxidant propertiesBuChEcholinesterase inhibitorsmetal-chelating propertiesmultifunctional ligands

Identifiers

PMID36012707
PMCPMC9409043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.